Editorial: effectiveness and safety of vedolizumab in a matched cohort of elderly and non-elderly patients with inflammatory bowel disease - the IG-IBD LIVE study

Aliment Pharmacol Ther. 2022 Aug;56(4):731-732. doi: 10.1111/apt.16957.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Aged
  • Antibodies, Monoclonal, Humanized / adverse effects
  • Cohort Studies
  • Humans
  • Inflammatory Bowel Diseases* / drug therapy
  • Middle Aged

Substances

  • Antibodies, Monoclonal, Humanized
  • vedolizumab